Esperion Therapeutics (ESPR) News Today $0.85 -0.06 (-6.13%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.11%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $6.25May 20 at 1:39 AM | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by BrokeragesShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given aMay 19 at 4:19 AM | marketbeat.comEsperion Settles Patent Litigation With Micro Labs For Generic NexletolMay 14, 2025 | nasdaq.comEsperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040May 12, 2025 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for ESPR EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company willMay 11, 2025 | marketbeat.comEsperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor ConferenceMay 9, 2025 | theglobeandmail.comEsperion Therapeutics (NASDAQ:ESPR) Price Target Lowered to $4.00 at Needham & Company LLCNeedham & Company LLC dropped their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comEsperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor ConferenceMay 9, 2025 | globenewswire.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 8, 2025 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Announces Earnings ResultsEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03).May 8, 2025 | marketbeat.comEsperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in CanadaMay 8, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comEsperion Therapeutics Inc (ESPR) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 7, 2025 | finance.yahoo.comEsperion Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comZacks Research Has Optimistic Outlook of ESPR Q1 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research boosted their Q1 2026 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will pMay 2, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Reduced by Renaissance Technologies LLCRenaissance Technologies LLC trimmed its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 36.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 578,800 shares of the biopharmaceutical company's stock after selling 335,300 shares durMay 2, 2025 | marketbeat.comResearch Analysts Set Expectations for ESPR FY2027 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research boosted their FY2027 earnings estimates for shares of Esperion Therapeutics in a research note issued to investors on Monday, April 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will poMay 1, 2025 | marketbeat.comEsperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-esperion-therapeutics-inc-stock/)May 1, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) is Indaba Capital Management L.P.'s 10th Largest PositionIndaba Capital Management L.P. lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 91.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,000,000 shares of the biophaApril 30, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Esperion Therapeutics in a research note on Friday.April 27, 2025 | marketbeat.comEsperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Friday.April 27, 2025 | marketbeat.comEsperion to Participate in The Citizens Life Sciences ConferenceApril 25, 2025 | globenewswire.comEsperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025April 24, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one hasApril 24, 2025 | marketbeat.comEsperion to Report First Quarter 2025 Financial Results on May 6April 23, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Stock ForecastsApril 23, 2025 | ca.finance.yahoo.comEsperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...April 21, 2025 | finance.yahoo.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Holdings Lifted by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 18.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,454,216 shares of the biopharmApril 20, 2025 | marketbeat.comWasatch Advisors LP Purchases 1,136,245 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wasatch Advisors LP boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,482,258 shares of the biopharmApril 18, 2025 | marketbeat.comVanguard Group Inc. Has $25.78 Million Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Vanguard Group Inc. cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,715,748 shares of the biopharmaceutical company's stock afteApril 16, 2025 | marketbeat.comCenterBook Partners LP Has $2.87 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)CenterBook Partners LP lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 58.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,306,259 shares of the biopharmaApril 12, 2025 | marketbeat.comEsperion to host R&D Day to highlight cardiometabolic pipelineApril 11, 2025 | markets.businessinsider.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a report on Tuesday.April 10, 2025 | marketbeat.comEsperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025April 10, 2025 | globenewswire.comEsperion (ESPR) Gets a Buy from NeedhamApril 8, 2025 | markets.businessinsider.comEsperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?April 3, 2025 | msn.comEsperion appoints Hoffman to board of directorsApril 2, 2025 | markets.businessinsider.comDiametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Diametric Capital LP lessened its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 46.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 354,010 shares of the biopharmaceutical company's stock after selling 312,829 shares durinApril 2, 2025 | marketbeat.comEsperion Appoints Robert E. Hoffman to Board of DirectorsApril 1, 2025 | globenewswire.comZacks Research Issues Negative Outlook for ESPR EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 25th. Zacks Research analyst K. Das now forecasts that the biopharmaceuMarch 29, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by AnalystsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a holMarch 29, 2025 | marketbeat.comWhat is Zacks Research's Estimate for ESPR FY2027 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das expects that the biopharmaMarch 28, 2025 | marketbeat.comEsperion to Participate in 24th Annual Needham Virtual Healthcare ConferenceMarch 24, 2025 | markets.businessinsider.comVictory Capital Management Inc. Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Victory Capital Management Inc. boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 602.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,083 shares of the biMarch 23, 2025 | marketbeat.comEsperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acidMarch 21, 2025 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comPlatinum Investment Management Ltd. Sells 252,810 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Platinum Investment Management Ltd. cut its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 840,052 shareMarch 20, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 932,008 shares ofMarch 19, 2025 | marketbeat.comESPR FY2025 EPS Estimate Boosted by Cantor FitzgeraldEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now antiMarch 15, 2025 | marketbeat.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.210.65▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼24▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ArriVent BioPharma News Today Day One Biopharmaceuticals News Today Trevi Therapeutics News Today Immatics News Today Vir Biotechnology News Today Sionna Therapeutics News Today Evolus News Today Replimune Group News Today Pharming Group News Today Dianthus Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
